Literature DB >> 24136293

Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat.

Natalia Gass1, Adam James Schwarz2, Alexander Sartorius3, Esther Schenker4, Celine Risterucci5, Michael Spedding4, Lei Zheng6, Andreas Meyer-Lindenberg7, Wolfgang Weber-Fahr1.   

Abstract

Dysfunctional connectivity within the hippocampal-prefrontal circuit (HC-PFC) is associated with schizophrenia, major depression, and neurodegenerative disorders, and both the hippocampus and prefrontal cortex have dense populations of N-methyl-D-aspartate (NMDA) receptors. Ketamine, a potent NMDA receptor antagonist, is of substantial current interest as a mechanistic model of glutamatergic dysfunction in animal and human studies, a psychotomimetic agent and a rapidly acting antidepressant. In this study, we sought to understand the modulatory effect of acute ketamine administration on functional connectivity in the HC-PFC system of the rat brain using resting-state fMRI. Sprague-Dawley rats in four parallel groups (N=9 per group) received either saline or one of three behaviorally relevant, sub-anesthetic doses of S-ketamine (5, 10, and 25 mg/kg, s.c.), and connectivity changes 15- and 30-min post-injection were studied. The strongest effects were dose- and exposure-dependent increases in functional connectivity within the prefrontal cortex and in anterior-posterior connections between the posterior hippocampus and retrosplenial cortex, and prefrontal regions. The increased prefrontal connectivity is consistent with ketamine-induced increases in HC-PFC electroencephalographic gamma band power, possibly reflecting a psychotomimetic aspect of ketamine's effect, and is contrary to the data from chronic schizophrenic patients suggesting that ketamine effect does not necessarily parallel the disease pattern but might rather reflect a hyperglutamatergic state. These findings may help to clarify the brain systems underlying different dose-dependent behavioral profiles of ketamine in the rat.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24136293      PMCID: PMC3924524          DOI: 10.1038/npp.2013.290

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  50 in total

1.  Comparison of alpha-chloralose, medetomidine and isoflurane anesthesia for functional connectivity mapping in the rat.

Authors:  Kathleen A Williams; Matthew Magnuson; Waqas Majeed; Stephen M LaConte; Scott J Peltier; Xiaoping Hu; Shella D Keilholz
Journal:  Magn Reson Imaging       Date:  2010-04-24       Impact factor: 2.546

2.  Effects of ketamine and pentobarbital on noradrenaline release from the medial prefrontal cortex in rats.

Authors:  T Kubota; N Anzawa; K Hirota; H Yoshida; T Kushikata; A Matsuki
Journal:  Can J Anaesth       Date:  1999-04       Impact factor: 5.063

3.  Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia.

Authors:  Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

4.  Differential effects of ketamine and pentobarbitone on acetylcholine release from the rat hippocampus and striatum.

Authors:  K Sato; J Wu; T Kikuchi; Y Wang; I Watanabe; F Okumura
Journal:  Br J Anaesth       Date:  1996-09       Impact factor: 9.166

5.  Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.

Authors:  O M Doyle; S De Simoni; A J Schwarz; C Brittain; O G O'Daly; S C R Williams; M A Mehta
Journal:  J Pharmacol Exp Ther       Date:  2013-01-31       Impact factor: 4.030

6.  Differential effects of NMDA antagonists on high frequency and gamma EEG oscillations in a neurodevelopmental model of schizophrenia.

Authors:  K G Phillips; M C Cotel; A P McCarthy; D M Edgar; M Tricklebank; M J O'Neill; M W Jones; K A Wafford
Journal:  Neuropharmacology       Date:  2011-04-19       Impact factor: 5.250

7.  Time, action and psychosis: using subjective time to investigate the effects of ketamine on sense of agency.

Authors:  J W Moore; V C Cambridge; H Morgan; F Giorlando; R Adapa; P C Fletcher
Journal:  Neuropsychologia       Date:  2012-07-17       Impact factor: 3.139

8.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

9.  Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.

Authors:  Milan Scheidegger; Martin Walter; Mick Lehmann; Coraline Metzger; Simone Grimm; Heinz Boeker; Peter Boesiger; Anke Henning; Erich Seifritz
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.

Authors:  N R Driesen; G McCarthy; Z Bhagwagar; M Bloch; V Calhoun; D C D'Souza; R Gueorguieva; G He; R Ramachandran; R F Suckow; A Anticevic; P T Morgan; J H Krystal
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

View more
  41 in total

Review 1.  Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry.

Authors:  Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven
Journal:  Hum Brain Mapp       Date:  2017-02-01       Impact factor: 5.038

2.  Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats.

Authors:  Oliver Grimm; Natalia Gass; Wolfgang Weber-Fahr; Alexander Sartorius; Esther Schenker; Michael Spedding; Celine Risterucci; Janina Isabel Schweiger; Andreas Böhringer; Zhenxiang Zang; Heike Tost; Adam James Schwarz; Andreas Meyer-Lindenberg
Journal:  Psychopharmacology (Berl)       Date:  2015-07-18       Impact factor: 4.530

3.  Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function.

Authors:  Yukitoshi Izumi; Charles F Zorumski
Journal:  Neuropharmacology       Date:  2014-08-13       Impact factor: 5.250

Review 4.  Functional magnetic resonance imaging of intrinsic brain networks for translational drug discovery.

Authors:  Jason Smucny; Korey P Wylie; Jason R Tregellas
Journal:  Trends Pharmacol Sci       Date:  2014-06-03       Impact factor: 14.819

5.  Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.

Authors:  Kristian Gaarn du Jardin; Nico Liebenberg; Heidi Kaastrup Müller; Betina Elfving; Connie Sanchez; Gregers Wegener
Journal:  Psychopharmacology (Berl)       Date:  2016-05-28       Impact factor: 4.530

Review 6.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

7.  Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.

Authors:  L Becerra; J Bishop; G Barmettler; Y Xie; E Navratilova; F Porreca; D Borsook
Journal:  J Neurophysiol       Date:  2015-10-21       Impact factor: 2.714

Review 8.  Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.

Authors:  Marc S Lener; Mark J Niciu; Elizabeth D Ballard; Minkyung Park; Lawrence T Park; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2016-05-12       Impact factor: 13.382

9.  Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy.

Authors:  Dávid Nagy; Milan Stoiljkovic; Frank S Menniti; Mihály Hajós
Journal:  Neuropsychopharmacology       Date:  2015-09-25       Impact factor: 7.853

Review 10.  Multistage drug effects of ketamine in the treatment of major depression.

Authors:  Martin Walter; Shijia Li; Liliana Ramona Demenescu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-13       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.